We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$279M
Cap. Flow %
-2.91%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 89.03%
2 Financials 0.34%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYNA
76
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$17.5M 0.18%
1,140,325
– –
MOH icon
77
CALL
Molina Healthcare
MOH
$10.6B
$17.5M 0.18%
+350,000
New +$18.7M
XNCR icon
78
Xencor
XNCR
$1.45B
$16.5M 0.17%
870,822
-236,200
-21% -$3.24M
SVA
79
DELISTED
Sinovac Biotech, Ltd
SVA
$15.8M 0.17%
2,667,500
– –
LAB icon
80
Standard BioTools
LAB
$323M
$15.8M 0.16%
1,746,100
– –
NTRA icon
81
Natera
NTRA
$36.5B
$15.4M 0.16%
1,276,190
– –
NUVA
82
DELISTED
NuVasive, Inc.
NUVA
$14.8M 0.15%
247,100
-1,239,900
-83% -$67M
FWP
83
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$14.5M 0.15%
114,000
– –
AET
84
DELISTED
Aetna Inc
AET
$14.2M 0.15%
116,600
+40,600
+53% +$4.66M
IBB icon
85
iShares Biotechnology ETF
IBB
$9.51B
$13.7M 0.14%
159,900
-175,200
-52% -$15.7M
CAH icon
86
Cardinal Health
CAH
$54.6B
$12.9M 0.14%
166,000
– –
JAZZ icon
87
Jazz Pharmaceuticals
JAZZ
$16.1B
$12.7M 0.13%
90,000
– –
PVLA
88
Palvella Therapeutics
PVLA
$2.03B
$11.7M 0.12%
90,745
– –
PRQR icon
89
ProQR Therapeutics
PRQR
$246M
$11.2M 0.12%
2,305,446
– –
RCKT icon
90
Rocket Pharmaceuticals
RCKT
$336M
$10.3M 0.11%
347,750
– –
NBRV
91
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.86M 0.1%
5,260
– –
AFMD
92
DELISTED
Affimed
AFMD
$9.36M 0.1%
377,500
-15,680
-4% -$573K
ABT icon
93
Abbott
ABT
$190B
$9.32M 0.1%
237,000
– –
CLLS
94
Cellectis
CLLS
$287M
$9.31M 0.1%
350,000
– –
SIEN
95
DELISTED
Sientra, Inc.
SIEN
$8.93M 0.09%
135,750
– –
IMMU
96
DELISTED
Immunomedics Inc
IMMU
$8.82M 0.09%
3,802,000
– –
PTLA
97
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.75M 0.09%
370,900
-467,200
-56% -$11.5M
RARE icon
98
Ultragenyx Pharmaceutical
RARE
$2.53B
$8.28M 0.09%
169,300
+41,000
+32% +$2.65M
MCK icon
99
McKesson
MCK
$106B
$8.1M 0.08%
43,400
-33,800
-44% -$5.93M
ASMB icon
100
Assembly Biosciences
ASMB
$496M
$7.75M 0.08%
116,425
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q2 2016 filing shows 16 new, 39 increased, 32 reduced and 21 closed positions. Its largest new stake was Molina Healthcare: 1,838,000 shares worth $91.7M. The largest sale was Bristol-Myers Squibb, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.